Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC
To evaluate the safety and efficacy of aprepitant combined with ondansetron and dexamethasone to prevent nausea and vomiting induced by Intensity-modulated Radiotherapy (IMRT) cisplatin-chemotherapy regimen in locally advanced squamous cell carcinoma of head and neck
Vomiting|Nausea Post Chemotherapy|Head Neck Cancer
DRUG: Aprepitant
Complete response rate, no vomiting and nausea, and no use of rescue therapy, up to 8 weeks
Complete response rate, no vomiting and nausea, and no use of rescue therapy, up to 3 weeks|Complete response rate, no vomiting and nausea, and no use of rescue therapy, up to 6 weeks|European Organization for Research on Treatment of Cancer Quality of life questionnaire, Quality of life questionnaire core 30 chinese version is used. The total score is reported, and the high values represent a worse outcome., up to 12 weeks
To evaluate the complete response rate, nause-free rate, vomiting-free rate, and the quality of life of aprepitant combined with ondansetron and dexamethasone for the nausea and vomiting induced by chemoradiotherapy in HNSCC.